Psychiatric treatment considerations with direct acting antivirals in hepatitis C

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Sockalingam, Sanjeev ^a,b   Tseng, Alice ^b,c   Giguere, Pierre ^d,e   Wong, David ^f,g  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Boceprevir; Hepatitis C; Mental disorders; Psychotropic drugs; Telaprevir

Indexed keywords

ALPHA INTERFERON; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BOCEPREVIR; BUPRENORPHINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; ESCITALOPRAM; HYPERICUM PERFORATUM EXTRACT; HYPNOTIC AGENT; LAMOTRIGINE; METHADONE; MIDAZOLAM; MOOD STABILIZER; MULTIDRUG RESISTANCE PROTEIN; NALOXONE; NEUROLEPTIC AGENT; PALIPERIDONE; PIMOZIDE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TELAPREVIR; TRIAZOLAM; UNINDEXED DRUG; ZOLPIDEM;

AGRANULOCYTOSIS; ANXIETY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; BONE MARROW SUPPRESSION; CONFUSION; DELIRIUM; DEPRESSION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG USE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; MEDICATION COMPLIANCE; NAUSEA; NEUTROPENIA; OPIATE ADDICTION; PATIENT MONITORING; PROTEIN PROTEIN INTERACTION; PSYCHIATRIC TREATMENT; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RISK FACTOR; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SWEATING; TONIC CLONIC SEIZURE;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C; HUMANS; MEDICATION ADHERENCE; MENTAL DISORDERS; OLIGOPEPTIDES; PROLINE; PSYCHOTROPIC DRUGS;

EID: 84877586800     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-86     Document Type: Article

References (92)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20(1):1-16. 10.1055/s-2000-9506, 10895436.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982. 10.1056/NEJMoa020047, 12324553.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965. 10.1016/S0140-6736(01)06102-5, 11583749.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364(25):2405-2416. 10.1056/NEJMoa1012912, 21696307.
5. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206. 10.1056/NEJMoa1010494, 21449783.
6. El-Sarag HB, Kunik M, Richardson P, Rabaneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002, 123:476-482. 10.1053/gast.2002.34750, 12145801.
7. Yovtcheva SP, Rifai MA, Moles JK, Linden BJV. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001, 42:411-415. 10.1176/appi.psy.42.5.411, 11739908.
8. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psych 2003, 25:34-38.
9. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010, 51(5):401-408. 2994596, 20833939.
10. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007, 103:83-90. 10.1016/j.jad.2007.01.007, 17292481.
11. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7(9):942-947. 10.1038/sj.mp.4001119, 12399946.
12. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willnebring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych 2004, 26:237-240.
13. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2001, 42(4):365-367. 10.1176/appi.psy.42.4.365, 11496031.
14. Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat 2011, 18(3):153-160. 10.1111/j.1365-2893.2010.01393.x, 21070503.
15. Schaefer M, Hintzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007, 46:991-998. 10.1002/hep.21791, 17668880.
16. Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol 2010, 44(9):e210-217. 10.1097/MCG.0b013e3181d88af5, 20838237.
17. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care 2012, 24(12):1504-1513. 10.1080/09540121.2012.672718, 22530794.
18. Vertex Pharmaceuticals Inc Incivek (telaprevir) Product Monograph 2012, Cambridge, MA: Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals Inc.
19. Merck Canada Inc Victrelis (boceprevir) Product Monograph January 16, 2013, Kirkland, QC: Merck Canada Inc, Merck Canada Inc.
20. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012, 84(8):1096-1102. 10.1016/j.bcp.2012.07.032, 22902721.
21. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006, 8(1):E101-111. 10.1208/aapsj080112, 2751428, 16584116.
22. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002, 162(4):405-412. 10.1001/archinte.162.4.405, 11863472.
23. Kipp G, Mohammad R, Lin A, Johnson H. Evaluation of pharmacist identified and mitigated drug-drug interactions in hepatitis C virus infected patients starting telaprevir or boceprevir. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases 2012, Boston, MA.
24. Hulskotte EGJ, Feng H-P, Xuan F, van Zutven M, O'Mara E, Youngberg S, Wagner JA, Butterton JR. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Clin Infect Dis 2013, 56(5):718-726. 10.1093/cid/cis968, 23155151.
25. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010, 15(3):413-423. 10.3851/IMP1540, 20516560.
26. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psychiatry 2009, 54(9):614-625.
27. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM. Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. J Hepatol 2012, 57(6):1379-1390. 10.1016/j.jhep.2012.07.037, 22878466.
28. Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry 2012, 24(1):91-109.
29. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol 2012, 32(4):531-543. 10.1097/JCP.0b013e31825d9982, 22722514.
30. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11(3):225-255. 10.1111/j.1399-5618.2009.00672.x, 19419382.
31. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365(11):1014-1024. 10.1056/NEJMoa1014463, 21916639.
32. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364(25):2417-2428. 10.1056/NEJMoa1013086, 21696308.
33. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376(9742):705-716. 10.1016/S0140-6736(10)60934-8, 20692693.
34. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1207-1217. 10.1056/NEJMoa1009482, 3153125, 21449784.
35. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Helnze L, Spengler U, Schlaepfer T, Relmer J, Bugglsch P. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med 2012, 157:94-103. 10.7326/0003-4819-157-2-201207170-00006, 22801672.
36. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-A pilot study. Dig Dis Sci 2007, 52(10):2557-2563. 10.1007/s10620-006-9729-5, 17436092.
37. Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, Wagner JA, Butterton JR. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Global Antiviral Journal 2011, 7(1):108-109. abstract.
38. Van Heeswijk RPG, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beaumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Rev Antiviral Ther Infect Dis 2010, 5:12-13.
39. Nichols AI, Behrle JA, Parks V, Richards LS, McGrory SB, Posener J, Patat A, Paul J. Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reupatke inhibitor. J Bioequiv Availab 2013, 5:1.
40. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Current drug metabolism 2008, 9(5):394-409. 10.2174/138920008784746391, 3654441, 23682315.
41. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004, 18(1):41-46. 10.1177/0269881104040230, 15107183.
42. Dieperink E, Leskela J, Dieperink ME, Evans B, Thuras P, Ho SB. The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics 2008, 49(3):225-229. 10.1176/appi.psy.49.3.225, 18448777.
43. Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004, 45(1):29-33. 10.1176/appi.psy.45.1.29, 14709758.
44. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002, 63(3):194-198. 10.4088/JCP.v63n0304, 11926717.
45. Gleason OC, Yates WR, Philipsen MA. Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry 2005, 7(5):225-230. 10.4088/PCC.v07n0503, 1257407, 16308578.
46. Swinson RP, Antony MM, Bleau P, Chokka P, Craven M, Fallu A, Katzman M, Kjernisted K, Lanius R, Manassis K. Clinical Practice Guidelines: Management of Anxiety DIsorders. Can J Psychiatry 2006, 51(8):2.
47. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013, 346:f288. 10.1136/bmj.f288, 3558546, 23360890.
48. Lundbeck Canada Inc Celexa (citalopram) Product Monograph 2012, Montreal, QC: Lundbeck Canada Inc, Lundbeck Canada Inc.
49. Lundbeck Canada Inc Cipralex (escitalopram) Product Monograph 2012, Montreal, QC: Lundbeck Canada Inc, Lundbeck Canada Inc.
50. DeMaio W, Kane CP, Nichols AI, Jordan R. Metabolism studies of desvenlafaxine. J Bioequiv Availab 2011, 3:151-160.
51. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000, 54:565-572. 10.1046/j.1440-1819.2000.00754.x, 11043807.
52. Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005, 37(2):102-107. 10.1016/j.dld.2004.09.018, 15733522.
53. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983, 3(6):913-918.
54. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections 2011, Boston, USA.
55. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, Van Heeswijk RPG. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012, 52(10):1566-1573. 10.1177/0091270011419850, 22162542.
56. Luo X, Van Heeswijk RPG, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11]. Rev Antiviral Ther Infect Dis 2011, 6:13.
57. Rifai MA. Hepatitis C treatment of patients with bipolar disorder: a case series. Prim Care Companion J Clin Psychiatry 2006, 8(6):361-366. 10.4088/PCC.v08n0607, 1764521, 17245458.
58. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984, 25(6):673-681. 10.1136/gut.25.6.673, 1432377, 6428980.
59. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry 2003, 160(1):174-178. 10.1176/appi.ajp.160.1.174, 12505820.
60. Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems 2009, 39(5):355-363. 10.1080/00498250902745082, 23679834.
61. Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 2012, 24(1):6-22.
62. Novartis Pharmaceuticals Canada Inc Tegretol (Carbamazepine) Product Monograph 2011, Dorval, Que: Novartis Pharmaceuticals Canada Inc, Novartis Pharmaceuticals Canada Inc.
63. Andreasen AH, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia 2007, 48(3):490-496. 10.1111/j.1528-1167.2007.00924.x, 17346248.
64. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002, 24(1):91-103. 10.1097/00007691-200202000-00016, 11805729.
65. Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics 2007, 48(5):405-411. 10.1176/appi.psy.48.5.405, 17878499.
66. Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Determining rates of hepatitis C in a clozapine treated cohort. Schizophr Res 2010, 124(1-3):86-90.
67. Matthews AM, Huckans MS, Blackwell AD, Hauser P. Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord 2008, 10(2):266-270. 10.1111/j.1399-5618.2007.00472.x, 18271905.
68. Telio D, Sockalingam S, Stergiopoulos V. Persistent psychosis after treatment with interferon alfa: a case report. J Clin Psychopharmocol 2006, 26(4):446-447.
69. Thome J, Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry 2003, 18:142-143. 10.1016/S0924-9338(03)00030-0, 12763304.
70. Garcia-Pares G, Domenech C, Gil M. Psychosis induced by interferon-alpha. Psychosomatics 2002, 43:428-429. 10.1176/appi.psy.43.5.428, 12297615.
71. Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller M, Condermarin JR, Chiu NM, Jacobson JM. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2003, 44:417-420. 10.1176/appi.psy.44.5.417, 12954918.
72. Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000, 95(7):1101-1104.
73. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, Henry C. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005, 66(8):1050-1057. 10.4088/JCP.v66n0814, 16086622.
74. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004, 161(3):429-435. 10.1176/appi.ajp.161.3.429, 14992966.
75. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004, 24(1):62-69. 10.1097/01.jcp.0000104913.75206.62, 14709949.
76. Merck Canada Inc. MC Saphris (asenapine) Product Monograph 2013, Kirkland, QC: Merck Canada Inc, Merck Canada Inc. MC.
77. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997, 44(5):439-446. 2042873, 9384460.
78. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007, 100(1):4-22. 10.1111/j.1742-7843.2007.00017.x, 17214606.
79. English BA, Dortch M, Ereshefsky L, Jhee S. Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep 2012, 14(4):376-390. 10.1007/s11920-012-0284-9, 22707017.
80. AstraZeneca Canada Inc Seroquel (quetiapine) Product Monograph 2013, Mississauga, ON: AstraZeneca Canada Inc, April 16, AstraZeneca Canada Inc.
81. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013, 28(1):50-56. 10.1097/YIC.0b013e32835ac9da, 23104241.
82. Liukkonen T, Sorjonen M, Jokelainen J, Timonen M. Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment. Psychosomatics 2008, 49(1):86-88.
83. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002, 71(2):163-169. 10.1016/S0024-3205(02)01680-6, 12031686.
84. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007, 19(9):741-747. 10.1097/MEG.0b013e3281bcb8d8, 17700258.
85. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010, 22(3):270-277. 10.1097/MEG.0b013e32832a8c4c, 20425880.
86. Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother 2012, 56(7):3641-3647. 10.1128/AAC.00077-12, 3393419, 22564847.
87. Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE. A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics 2011, 52(5):433-440.
88. Hulskotte EGJ, Hwa-Ping F, Bruce RD, Webster LR, Xuan F, O'Mara E, Wagner JA, Butterton JR. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09] 2012, Cambridge, MA: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Rev Antiviral Ther Infect Dis 2012; 6:12.
89. Dbouk B, Arguedas MR, Sheikh A. Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci 2008, 53:1100-1106. 10.1007/s10620-007-9985-z, 17934817.
90. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006, 101(10):2254-2262. 10.1111/j.1572-0241.2006.00731.x, 17032190.
91. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull 2010, 36(1):165-172. 10.1093/schbul/sbn065, 2800135, 18562341.
92. Sockalingam S, Blank D, Banga CA, Mason K, Dodd Z, Powis J. A novel program for treating patients with trimorbidity: hepatitis C, severe mental illness, and active substance use. Eur J Gastroenterol Hepatol 2013, in press.